Assessing cell activity balance during pregnancy
Autophagy/Apoptosis Balance During Pregnancy
This study looks at how certain cell activities change during pregnancy in women with normal pregnancies and those at risk for complications to see if these changes affect pregnancy outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Centre Hospitalier Universitaire de Nīmes Academic / other |
| Locations | 1 site (Nîmes) |
| Trial ID | NCT04443660 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the variability of apoptosis and autophagy activities in women during pregnancy, focusing on those with normal pregnancies and those at risk of complications. Investigators hypothesize that there is a dialogue between autophagy and apoptosis mechanisms within trophoblast cells, where increased autophagy may serve as a defense against apoptosis. Blood tests will be conducted to gather data on these cellular processes. The findings could provide insights into the cellular dynamics that affect pregnancy outcomes.
Who should consider this trial
Good fit: Ideal candidates are women who are under 33 weeks of gestation and are receiving care at CHU Nîmes.
Not a fit: Patients with multiple pregnancies or those participating in other interventional studies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of pregnancy complications and lead to improved management strategies for at-risk pregnancies.
How similar studies have performed: While the specific approach of assessing autophagy and apoptosis balance during pregnancy is novel, related studies have explored these mechanisms in other contexts with varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients followed at the CHU Nîmes prior to 33 weeks gestation who give birth at the hospital * The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan Exclusion Criteria: * The subject is participating in a category 1 interventional study associated with a medication, or is in a period of exclusion determined by a previous study * The subject refuses to sign the consent * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * Multiple pregnancy
Where this trial is running
Nîmes
- CHU de Nimes — Nîmes, France (Recruiting)
Study contacts
- Principal investigator: Sylvie Bouvier — CHU Nimes
- Study coordinator: Sylvie Bouvier
- Email: sylvie.bouvier@chu-nimes.fr
- Phone: 04.66.68.32.11
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.